The stock of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) increased by $5.48 on Monday to finish at $112.15, up 5.14 percent. The last five days have seen an average of 2,749,320 shares of common stock traded. 1 time new highs were reached in the current year, with a fall of -$1.65. The average number of shares traded over the last 20 days was 1,839,900, while the average volume over the last 50 days totaled 1,712,530.
HZNP stock appreciated 12.22% since last month. On 08/03/23, the company’s shares reached a one-month low of $98.80. The stock touched a high of $113.83 on 01/03/23, after rallying from a low of $57.84 in 52 weeks. The price of HZNP stock has declined by -1.45% or -$1.65 this year, reaching a new high 1 time. Still, the stock price is down -1.48% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
HZNP stock investors should be aware that Horizon Therapeutics Public Limited Company (HZNP) stock had its last reported insider trading activity 224 days ago on Jan 17. On Jan 17, EVP, Chief Strategy Officer Pasternak Andy sold 27,129 shares at $113.03 each. This transaction resulted in the insider making $3,066,323. On Jan 13, Cox Aaron sold 36,148 shares at a price of US$113.17. After the transaction, the insider now owns 277 shares. EVP and Chief Medical Officer SHERMAN JEFFREY W had earlier sold 3,368 shares on Jan 11 for $113.10 a share. The transaction was completed for $380,921.
Valuation Metrics
Horizon Therapeutics Public Limited Company (HZNP) has a trailing price-to-earnings (P/E) ratio of 59.94. Beta for the stock is 1.04. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 7.03, the price-to-book (PB) ratio of 4.83, and the price-to-cash flow ratio of 26.72.
Financial Health
For the three months ended June 29, Horizon Therapeutics Public Limited Company’s quick ratio was 4.10, while its current ratio was 4.30, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.48, and the total debt to equity ratio is 0.48. As far as profitability goes, gross margin for the trailing twelve months is 75.20% percent. Horizon Therapeutics Public Limited Company’s EBITDA margin for the year ended June 29 was 30.09%, whereas its operating margin stood at 14.10% for the same period. Based on annual data, it had gross profit of $2.71 billion and revenue of $3.63 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. HZNP’s return on assets (ROA) during the last 12 months has been 4.80%. There was a 8.00% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 8.50%.
Earnings Surprise
According to Horizon Therapeutics Public Limited Company’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $944.0 million, while revenues rose by 7.16% to $832.06 million. It was predicted that Horizon Therapeutics Public Limited Company’s quarterly earnings would be $1.2, but it ended up being $1.03, beating the consensus by 16.50%. EBITDA was $240.43 million for the quarter. At the end of Horizon Therapeutics Public Limited Company’s most recent quarter ended June 29, its liabilities totaled 3.99 billion, while its total debt was $2.73 billion. Equity owned by shareholders amounts to $229.0 million.
Technical Picture
Here’s a quick look at Horizon Therapeutics Public Limited Company’s (HZNP) price momentum from a technical perspective. As of 28 August, the RSI 9-day stood at 92.29%, suggesting the stock is Overbought, with a 23.31% historical volatility rate.
The stochastic %K and %D were 87.62% and 90.74% respectively, while the average true range (ATR) was 1.71. Based on the 14-day stochastic reading of 89.10%, the RSI (14) reading is 85.80%. On the 9-day MACD Oscillator, the stock is at 2.47, and the 14-day reading is at 3.03.
Analyst Ratings
In its analyst report released on November 01, 2022, H.C. Wainwright began covering Horizon Therapeutics Public Limited Company (NASDAQ: HZNP). The stock was rated as a Neutral by the brokerage firm. Analysts have assigned Horizon Therapeutics Public Limited Company (HZNP) an Hold rating. HZNP is a stock that is recommended for selling by 0 brokerage firms, while 6 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.
What is HZNP’s price target for the next 12 months?
The current consensus forecast for the stock is between $116.50 and $116.50, with a median target price of $116.50. In analyzing these forecasts, the average price target given by analysts for Horizon Therapeutics Public Limited Company (HZNP) is $116.50.
